High-mobility group box 2 reflects exacerbated disease characteristics and poor prognosis in non-small cell lung cancer patients
High-mobility group box 2 reflects exacerbated disease characteristics and poor prognosis in non-small cell lung cancer patients
复制标题
DOI：
10.1007/s11845-021-02549-8
复制
发表时间：
2021-02-26
影响因子：
2.1
通讯作者：
Liu, Jiaqi
中科院分区：
文献类型：
--
作者：
Lou, Ning;Zhu, Tingting;Liu, Jiaqi
背景高迁移率族蛋白2（HMGB 2）被认为是非小细胞肺癌（NSCLC）的癌基因，但其临床意义尚不清楚。本研究旨在探讨高迁移率族蛋白2（HMGB 2）与非小细胞肺癌（NSCLC）临床病理特征及预后的关系。方法选择133例非小细胞肺癌根治性切除患者。分别采用免疫组化法（蛋白表达）和逆转录定量聚合酶链反应法（基因表达）检测肿瘤标本和配对癌旁组织标本中HMGB 2的表达。结果HMGB 2蛋白在肿瘤组织中的表达高于癌旁组织，并能区分肿瘤组织和癌旁组织（曲线下面积（AUC）：0.775，95%可信区间（95%CI）：0.720-0.830）。HMGB 2蛋白的高表达与淋巴结（林恩）转移和TNM分期有关。此外，肿瘤HMGB 2蛋白高表达与无病生存期（DFS）较差相关，而HMGB 2蛋白表达与总生存期（OS）无关。HMGB 2 mRNA在肿瘤组织中的表达高于癌旁组织，对肿瘤组织与癌旁组织的鉴别诊断有较好的价值（AUC：0.875，95% CI：0.834-0.915）。此外，肿瘤HMGB 2 mRNA高表达与较高的东部肿瘤协作组体能状态评分、林恩转移和晚期TNM分期相关。结论HMGB 2可作为反映NSCLC疾病特征和预后的生物标志物，有助于提高NSCLC患者的临床疗效。
Background High-mobility group box 2 (HMGB2) is considered as oncogene in non-small cell lung cancer (NSCLC), while its clinical implication is still unknown. This study aimed to explore the correlation of HMGB2 with clinicopathological characteristics and prognosis in NSCLC patients. Methods A total of 133 NSCLC patients who received radical excision were enrolled. HMGB2 expression in the tumor specimens and paired adjacent tissue specimens was determined by immunohistochemical assay (for protein expression) and reverse transcription quantitative polymerase chain reaction assay (for gene expression), respectively. Results HMGB2 protein expression was higher in tumor tissue compared with adjacent tissue, and it could distinguish tumor tissue from adjacent tissue (area under the curve (AUC): 0.775, 95%confidence interval (95%CI): 0.720-0.830). Meanwhile, tumor HMGB2 protein high expression correlated with lymph node (LYN) metastasis and advanced TNM stage. Additionally, tumor HMGB2 protein high expression associated with worse disease-free survival (DFS), while HMGB2 protein expression did not correlate with overall survival (OS). Besides, HMGB2 mRNA expression was raised in tumor tissue compared with adjacent tissue, and it had a good value in differentiating tumor tissue from adjacent tissue (AUC: 0.875, 95% CI: 0.834-0.915). Furthermore, tumor HMGB2 mRNA high expression correlated with higher Eastern Cooperative Oncology Group performance status score, LYN metastasis, and advanced TNM stage. Meanwhile, tumor HMGB2 mRNA high expression associated with shorter DFS and OS. Conclusion HMGB2 could be a biomarker that reflects disease features and prognosis of NSCLC, which is beneficial to improve clinical efficacy in NSCLC patients.